Skin cancers after organ transplantation

New England Journal of Medicine

Volumn 348, Issue 17, 2003, Pages 1681-1691

  Euvrard, Sylvie ^a   Kanitakis, Jean ^b   Claudy, Alain ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEXAROTENE; BLEOMYCIN; CISPLATIN; CYCLOSPORIN; DACTINOMYCIN; DAUNORUBICIN; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; ETRETIN; ETRETINATE; FLUOROURACIL; ISOTRETINOIN; PACLITAXEL; RAPAMYCIN; RETINOIC ACID; RETINOID DERIVATIVE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

AGE; ANUS CARCINOMA; ARTHRALGIA; AUSTRALIA; BASAL CELL CARCINOMA; BOWEN DISEASE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CARCINOGENESIS; CAUTERIZATION; CHEMOSURGERY; COMBINATION CHEMOTHERAPY; CRYOTHERAPY; CURETTAGE; DISEASE ASSOCIATION; DISEASE SEVERITY; DISEASE TRANSMISSION; DYSPLASIA; ETHNIC GROUP; GRAFT REJECTION; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE CARCINOMA; JAPAN; KAPOSI SARCOMA; KERATOACANTHOMA; KERATOSIS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOMA; MELANOMA; METASTASIS; NEUROENDOCRINE SYSTEM; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK FACTOR; SCANDINAVIA; SKIN CARCINOMA; SKIN DEFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TIME; TUMOR DIAGNOSIS; VERRUCA VULGARIS; XEROSIS;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOSUPPRESSION; MALE; MELANOMA; ORGAN TRANSPLANTATION; RISK FACTORS; SARCOMA, KAPOSI; SKIN NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 0037464506     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra022137     Document Type: Review

References (100)

1. Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc 1997;29:828-30.
2. Hiesse C, Rieu P, Kriaa F, et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc 1997;29:831-3.
3. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol 2001;27:409-13.
4. Sanchez EQ, Marubashi S, Jung G, et al. De novo tumors after liver transplantation: a single-institution experience. Liver Transplant 2002;8:285-91.
5. Bouwes-Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 1996; 61:715-21.
6. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40:177-86.
7. Hartevelt MM, Bavinck JN, Kootte AMM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990;49:506-9.
8. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002;147: 950-6.
9. Lindelöf B, Sigurgeirsson B, Gäbel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000;143:513-9.
10. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995;33:222-9.
11. Ishikawa N, Tanabe K, Tokumoto T, et al. Clinical study of malignancies after renal transplantation and impact of routine screening for early detection: a single-center experience. Transplant Proc 2000;32:1907-10.
12. Liddington M, Richardson AJ, Higgins RM, et al. Skin cancer in renal transplant recipients. Br J Surg 1989;76:1002-5.
13. Cooper SM, Wojnarowska F. The accuracy of clinical diagnosis of suspected premalignant and malignant skin lesions in renal transplant recipients. Clin Exp Dermatol 2002;27:436-8.
14. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc 1995;27:1767-8.
15. Adamson R, Obispo E, Dychter S, et al. High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study. Transplant Proc 1998;30:1124-6.
16. Pollard JD, Hanasono MM, Mikulec AA, Le QT, Terris DJ. Head and neck cancer in cardiothoracic transplant recipients. Laryngoscope 2000;110:1257-61.
17. Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 1999;85:1758-64.
18. Martinez JC, Otley CC, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003;139:301-6.
19. Penn I. De novo malignancies in pediatric organ transplant recipients. Pediatr Transplant 1998;2:56-63.
20. Euvrard S, Kanitakis J, Cochat P, Cambazard F, ClaudyA. Skin diseases in children with organ transplants. J Am Acad Dermatol 2001;44:932-9.
21. BavinckJN, De Boer A, Vermeer BJ, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993;129:242-9.
22. Espana A, Martinez-Gonzalez MA, Garcia-Granero M, Sanchez-Carpintero I, Rabago G, Herreros J. A prospective study of incident nonmelanoma skin cancer in heart transplant recipients. J Invest Dermatol 2000; 115:1158-60.
23. McGregor JM, Berkhout RJM, Rozycka M, et al. p53 Mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status. Oncogene 1997;15:1737-40.
24. Ducloux D, Carron PL, Rebibou JM, et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998;65:1270-2.
25. Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102:Suppl III:III-222-III-227.
26. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-8.
27. Frezza EE, Fung JJ, van Thiel DH. Nonlymphoid cancer after liver transplantation. Hepatogastroenterology 1997;44:1172-81.
28. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992;53:1051-6.
29. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
30. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73:1565-72.
31. Euvrard S, Chardonnet Y, Pouteil-Noble C, et al. Association of skin malignancies with various and multiple carcinogenic and non carcinogenic human papillomaviruses in renal transplant recipients. Cancer 1993; 72:2198-206.
32. Harwood CA, Surentheran T, McGregor JM, et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000;61:289-97.
33. Arends MJ, Benton EC, McLaren KM, Stark LA, Hunter JA, Bird CC. Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer 1997;75 722-8.
34. de Jong-Tieben LM, Berkhout R, ter Schegget J, et al. The prevalence of human papillomavirus DNA in benign keratotic skin lesions of renal transplant recipients with and without a history ofskin cancer is equally high: a clinical study to assess risk factor: for keratotic skin lesions and skin cancer Transplantation 2000;69:44-9.
35. Berkhout R, Bouwes Bavinck J, ter Schegget J. Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients. J Clin Microbiol 2000;38:2087-96.
36. Boxman ILA, Berkhout RJM, Mulder LHC, et al. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997;108:712-5.
37. Ramsay HM, Harden RN, Reece S, et al. Polymorphism in glutathione S-transferase are associated with altered risk of nonmelanoma skin cancer in renal transplant recipients: a preliminary analysis. J Invest Dermatol 2001;117:251-5.
38. De Hertog SA, Wensveen CA, Bastiaen MT, et al. Relation between smoking and skin cancer. J Clin Oncol 2001;19:231-8.
39. Marshall SE, Bordea C, Wojnarowska F, Morris PJ, Welsh KI. p53 Codon 72 polymorphism and susceptibility to skin cancer after renal transplantation. Transplantation 2000;69:994-6.
40. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
41. Cairey-Remonnay S, Humbey O, Mougin C, et al. TP53 polymorphism of exon 4 at codon 72 in cutaneous squamous cell carcinoma and benign epithelial lesions of renal transplant recipients and immunocompetent individuals: lack of correlation with human papillomavirus status. J Invest Dermatol 2002;118:1026-31.
42. McGregor JM, Harwood CA, Brooks L, et al. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 2002; 119:84-90.
43. Marshall SE, Bordea C, Haldar N, et al. Glutathione S-transferase polymorphisms and skin cancer after renal transplantation. Kidney Int 2000;58:2186-93.
44. Bouwes Bavinck JN, Claas FH, Hardie DR, Green A, Vermeer BJ, Hardie IR, Relation between HLA antigens and skin cancer in renal transplant recipients in Queensland, Australia. J Invest Dermatol 1997;108: 708-11.
45. O'Connor DP, Kay EW, Leader M, Murphy GM, Atkins GJ, Mabruk MJ. A high degree ofchromosomal instability at 13q14 in cutaneous squamous cell carcinomas: indication for a role of a tumour suppressor gene other than Rb. Mol Pathol 2001;54:165-9.
46. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-Retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235-41.
47. Magnone M, Holley JL, Shapiro R, et al. Interferon-α-induced acute renal allograft rejection. Transplantation 1995;59:1068-70.
48. Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001; 137:459-63.
49. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002;47:1-17.
50. Euvrard S, Kanitakis J, Thivolet J, et al. Retinoids for the management of dermatological complications of organ transplantation. Biodrugs 1997;3:176-84.
51. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995;13:1933-8.
52. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999;140:656-60.
53. Rook AH, Shapiro M. Cutaneous squamous-cell carcinoma. N Engl J Med 2001; 345:296.
54. Rook AH, Jaworsky C, Nguyen T, et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995; 59:714-9.
55. Euvrard S. Topical retinoids for the management of dysplastic epithelial lesions. In: Euvrard S, Kanitakis J, Claudy A, eds. Skin diseases after organ transplantation. Paris: John Libbey Eurotext, 1998:175-82.
56. Stockfleth E, Ulrich C, Meyer T, Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 2002;160:251-8.
57. Penn I. Cancers of the anogenital region in renal transplant recipients: analysis of 65 cases. Cancer 1986;58:611-6.
58. Sheil AGR, Flavel S, Disney APS, Mathew TH, Hall BM. Cancer incidence in renal transplant patients treated with azathioprine or cyclosporine. Transplant Proc 1987;19:2214-6.
59. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in nordic countries. Int J Cancer 1995;60:183-9.
60. Euvrard S, Kanitakis J, Chardonnet Y, et al. External anogenital lesions in organ transplant recipients: a clinicopathologic and virologic assessment. Arch Dermatol 1997; 133:175-8.
61. Sillman FH, Sentovich S, Shaffer D. Anogenital neoplasia in renal transplant patients. Ann Transplant 1997;2:59-66.
62. Harwood AR, Osoba D, Hofstader SL, et al. Kaposi's sarcoma in recipients of renal transplants. Am J Med 1979;67:759-65.
63. Woodle E, Hanaway M, Buell J, et al. Kaposi's sarcoma: an analysis of the US and international experiences from the Israel Penn International Transplant Tumor Registry. Transplant Proc 2001;33:3660-1.
64. Jenkins FJ, Hoffman LJ, Liegey-Dougall A. Reactivation of and primary infection with human herpesvirus 8 among solidorgan transplant recipients. J Infect Dis 2002;185:1238-43.
65. Qunibi W, Akhtar M, Sheth K, et al. Kaposi's sarcoma: the most common tumor after renal transplantation in Saudi Arabia. Am J Med 1988;84:225-32.
66. Ozen S, Saatci U, Karaduman A, et al. Kaposi's sarcoma in a paediatric renal transplant recipient. Nephrol Dial Transplant 1996;11:1162-3.
67. Farge D. Kaposi's sarcoma in organ transplant recipients. Eur J Med 1993;2:339-43.
68. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997;64:669-73.
69. Al-KhaderA, Suleiman M, Al-Hassani M, Haleem A. Posttransplant Kaposi sarcoma: staging as a guide to therapy and prognosis. Nephron 1988;48:165.
70. Boshoff C, Weiss RA. Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond Biol Sci 2001;356:517-34.
71. Noël JC, De Thier F, Heenen M, Fayt I, Abramowicz D, Doutrelepont JM. HHV-8 is associated with recurrent Kaposi's sarcoma in a renal transplant recipient. Transpl Int 1997;10:81-2.
72. Pellet C, Chevret S, Francès C, et al. Prognostic value of quantitative Kaposi sarcoma-associated herpesvirus load in posttransplantation Kaposi sarcoma. J Infect Dis 2002;186:110-3.
73. Cattani P, Capuano M, Graffeo R, et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in kidney transplant recipients. J Clin Microbiol 2001; 39:506-8.
74. Allen U. Human herpesvirus type 8 infections among solid organ transplant recipients. Pediatr Transplant 2002;6:187-92.
75. Moore PS. The emergence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8). N Engl J Med 2000;343:1411-3.
76. Francès C, Mouquet C, Marcellin AG, et al. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation 2000;69:1776-9.
77. Emond JP, Marcelin AG, Dorent R, et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in heart transplant recipients. J Clin Microbiol 2002; 40:2217-9.
78. Regamey N, Tamm M, Wernli M, et al. Transmission ofhuman herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998;339:1358-63.
79. Euvrard S, Kanitakis J, Brosshard C, et al. No recurrence of posttransplantation Kaposi's sarcoma three years after renal retransplantation. Transplantation 2002;73: 297-9.
80. Aseni P, Vertemati M, Minola E, et al. Kaposi's sarcoma in liver transplant recipients: morphological and clinical description. Liver Transpl 2001;7:816-23.
81. Barete S, Calvez V, Mouquet C, et al. Clinical features and contribution of virological findings to the management of Kaposi sarcoma in organ-allograft recipients. Arch Dermatol 2000;136:1452-8.
82. Shepherd FA, Maher E, Cardella C, et al. Treatment of Kaposis's sarcoma after solid organ transplantation. J Clin Oncol 1997; 15:2371-7.
83. Lévêque L, Dalac S, Dompmartin A, et al. Mélanome chez le transplanté. Ann Dermatol Venereol 2000;127:160-5.
84. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61:274-8.
85. Euvrard S, Kanitakis J, Claudy A. Neoplastic skin diseases in organ transplant recipients. Am J Cancer 2002;1:109-20.
86. Penn I, First MR. Merkel's skin carcinoma in organ recipients: report of 41 cases. Transplantation 1999;68:1717-21.
87. Mehrany K, Otley CC, Weenig RH, Phillips PK, Roenigk RK, Nguyen TH. A meta-analysis of the prognostic significance of sentinel lymph node status in Merkel cell carcinoma. Dermatol Surg 2002;28:113-7.
88. Friedlaender MM, Rubinger D, Rosenbaum E, Amir G, Siguencia E. Temporary regression of Merkel cell carcinoma metastases after cessation of cyclosporine. Transplantation 2002;73:1849-50.
89. De Carlis L, Slim A, De Gasperi A, et al. Posttransplant lymphoproliferative disorders: report from a single center. Transplant Proc 2001;33:2815-6.
90. Kapelushnik J, Ariad S, Benharroch D, et al. Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi's sarcoma. Br J Haematol 2001;113:425-8.
91. Mozzanica N, Cattaneo A, Fracchiola N, et al. Posttransplantation cutaneous B-cell lymphoma with monoclonal Epstein-Barr virus infection, responding to acyclovir and reduction in immunosuppression. J Heart Lung Transplant 1997;16:964-8.
92. Tas S, Simonart T, Dargent J-L, et al. Granulomatose lymphomatoïde à localisation cutanée isolée après une transplantation cardio-pulmonaire. Ann Dermatol Venereol 2000;127:488-91.
93. Euvrard S, Pouteil Noble C, Kanitakis J, et al. Successive occurrence of T-cell and B-cell lymphomas after renal transplantation in a patient with multiple cutaneous squamous-cell carcinomas. N Engl J Med 1992; 327:1924-6.
94. Penn I. Sarcomas in organ allograft recipients. Transplantation 1995;60:1485-91.
95. Wehrli BM, Janzen DL, Shokeir O, Masri BA, Byrne SK, O'Connell JX. Epithelioid angiosarcoma arising in a surgically constructed arteriovenous fistula: a rare complication of chronic immunosuppression in the setting of renal transplantation. Am J Surg Pathol 1998;22:1154-9.
96. Kanitakis J, Euvrard S, Montazeri A, et al. Atypical fibroxanthoma in a renal graft recipient. J Am Acad Dermatol 1996;35:262-4.
97. Paquet P, Pierard G. Invasive atypical fibroxanthoma and eruptive actinic keratoses in a heart transplant recipient. Dermatology 1996;192:411-3.
98. Butt A, Roberts DL. Renal transplant recipients and protection from sun: need for education. Lancet 1997;349:179-80.
99. Cowen EW, Billingsley EM. Awareness of skin cancer by kidney transplant patients. J Am Acad Dermatol 1999;40:697-701.
100. Otley CC. Organization of a specialty clinic to optimize the care of organ transplant recipients at risk for skin cancer. Dermatol Surg 2000;26:709-12.